GlassScriptPhysician profile
Marc D Glashofer
NPI 1851340418
$175,068.58
in general payments reported to CMS, 2019-2025
32 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,622 · 2020: $8,611 · 2021: $8,663 · 2022: $26K · 2023: $83K · 2024: $47K · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Travel and Lodging: $8,477 · Food and Beverage: $2,962 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $118,775.00 |
| Travel and Lodging | $8,476.65 |
| Food and Beverage | $2,961.81 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $156,544.18 | 2020-2024 | Olumiant, Taltz, Ebglyss |
| Eli Lilly and Company | $13,762.50 | 2020-2022 | |
| Allergan, INC. | $833.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $562.88 | 2019-2025 | |
| Abbvie INC. | $522.11 | 2019-2025 | |
| Janssen Biotech, INC. | $437.73 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Incyte Corporation | $369.53 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $233.40 | 2019-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $221.91 | 2019-2023 | Duobrii, Arazlo, Jublia |
| Sun Pharmaceutical Industries INC. | $179.92 | 2021-2025 | Odomzo, Blu-U |
| Ucb, INC. | $176.07 | 2019-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $147.64 | 2019-2022 | |
| Galderma Laboratories, L.P. | $142.86 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $128.32 | 2020-2023 | Dupixent |
| Amgen INC. | $116.40 | 2020-2024 | Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $112.75 | 2019-2021 | |
| Genzyme Corporation | $81.21 | 2019-2022 | |
| Epi Health, LLC | $70.52 | 2020-2022 | |
| Dermira, INC. | $67.45 | 2019-2020 | |
| Celgene Corporation | $67.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $48.66 | 2024 | Sotyktu |
| Almirall LLC | $42.43 | 2019-2020 | |
| Botanix Sb INC | $37.09 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $31.18 | 2024-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $26.63 | 2019 | |
| Sandoz INC. | $21.46 | 2020 | |
| Biofrontera INC. | $15.00 | 2021 | |
| Organogenesis INC. | $14.93 | 2023 | Puraply |
| Genentech USA, INC. | $14.39 | 2019 | |
| Encore Dermatology INC. | $14.29 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $12.77 | 2022 | |
| Glenmark Therapeutics INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Glashofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.